A provider, a payer, and an expert from an organization that endorses quality measures in healthcare participated in a panel discussion on measuring the quality of care in oncology.
Linda Bosserman, MD, assistant clinical professor and staff physician, City of Hope; Jason C. Goldwater, MA, MPA, senior director, National Quality Forum; and Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, came together in a panel discussion regarding the importance of quality measures, both in medicine and oncology specifically. Quality measures, the panelists agreed, are important resources that inspire improvement.
On a broader scale, Dr Malin explained that measuring quality is a necessary step for improvement and advancement in any industry. Understanding and reflecting upon what the company has done is key in being able to figure out what areas need improvement. According to Dr Malin, healthcare is no different.
“I think in most other industries, it would be a given that in order to improve your processes, you need to know what you’re doing today and to figure out if there’s a way to improve,” Dr Malin said. “And the same is true in healthcare. We may have come a little late to the party, but for many, many years, hundreds of years, we’ve done things in healthcare without really knowing [whether] we are doing it systematically—the right way or the wrong way.”
Dr Bosserman, who has worked in developing a medical home pilot program at City of Hope, added that improving quality in oncology begins when the company or organization itself measures its own successes and shortcomings. Only when the establishment understands what they’ve produced and the following outcomes can improvements be made for the future. In essence, measures are a means of reflection, a key ingredient in ensuring quality for all participating stakeholders.
“When we measure things, it’s that reality of what are we actually delivering, what do we know about it, and whether we can keep improving it,” Dr Bosserman said. “Without those facts, then we’re just thinking about things.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More